Shares of TRANSTHERA-B (ASX: 02617) have risen by more than 4%. At the time of writing, the stock is up 4.05% to HK$32.74, with a trading volume of HK$45.26 million.

The recent price movement follows a company announcement. TRANSTHERA-B disclosed that it presented new research findings for its core product, tenegotinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data, presented in a poster format, detailed the drug's performance as a monotherapy for treating advanced cholangiocarcinoma (bile duct cancer) in Chinese patients who had previously been treated with an FGFR inhibitor.

FGFR inhibitors are known to be effective against chemotherapy-refractory cholangiocarcinoma harboring FGFR2 alterations. However, treatment options become extremely limited for patients with advanced disease whose cancer progresses after both chemotherapy and FGFR inhibitor therapy.

Tenegotinib, a novel multi-target inhibitor, has demonstrated the ability to successfully overcome acquired resistance developed from prior FGFR inhibitor treatment. The data presented at ASCO detailed the efficacy and safety of tenegotinib in cholangiocarcinoma patients with FGFR2 alterations whose disease had progressed after receiving one prior FGFR inhibitor therapy.

These results originate from an open-label, multi-center Phase II clinical trial conducted in China, known as the FIRST-08 study.